Wetenschappelijke publicaties van Bordet

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids.

Agostini G, Leprovots M, Jeandriens J, Lefort A, Libert F, Sclafani F, Langer I, Hendlisz A, Garcia MI

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids.

Agostini G, Leprovots M, Jeandriens J, Lefort A, Libert F, Sclafani F, Langer I, Hendlisz A, Garcia MI

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids.

Corrigendum to \"Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies\" [Laboratory Investigation 105(2025) 104202].

Zels G, Pabba A, De Schepper M, Geukens T, Van Baelen K, Maetens M, Mahdami A, Leduc S, Isnaldi E, Nguyen HL, Bachir I, Van Cauwenberge J, Borremans K, Weynand B, Biganzoli E, Neven P, Wildiers H, Van Den Bogaert W, Richard F, Desmedt C, Floris G

Corrigendum to \"Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies\" [Laboratory Investigation 105(2025) 104202].

Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma.

Raddoux J, Kenis C, Vanhellemont A, Meers S, Mineur P, Vekemans MC, Wu KL, Caers J, Van Eygen K, Kentos A, Depaus J, Put N, Van De Velde A, Claes G, Vlummens P, Maertens V, Meuleman N, Broek IV, Vaes M, Fostier K, Demuynck H, Delforge M

Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma.

The prognostic value of PTEN expression in localized prostate cancer.

Bellouti A, Sirtaine N, Roumeguere T, Peltier A, Diamand R

The prognostic value of PTEN expression in localized prostate cancer.

Bellouti A, Sirtaine N, Roumeguere T, Peltier A, Diamand R

The prognostic value of PTEN expression in localized prostate cancer.

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Delbart W, Karfis I, Vercruyssen M, De Wind R, Meuleman N, Wimana Z, Flamen P, Woff E

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Delbart W, Karfis I, Vercruyssen M, De Wind R, Meuleman N, Wimana Z, Flamen P, Woff E

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Delbart W, Karfis I, Vercruyssen M, De Wind R, Meuleman N, Wimana Z, Flamen P, Woff E

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Bordet